Skip to main content
. 2023 Dec 5;24(24):17141. doi: 10.3390/ijms242417141

Figure 3.

Figure 3

Blocking SIGLEC-5/14 increases neutrophil ADCC against solid tumor cells. (a–d) Neutrophil ADCC against SKBR3 (a,c) or A431 (b,d) cells, in the presence or absence of monoclonal antibody trastuzumab or cetuximab, respectively. Neutrophils were stimulated with G-CSF/IFNγ overnight and pre-incubated with human SIGLEC-5/14 blocking antibody, where indicated (a: 15 donors from 8 independent experiments; b: 13 donors from 7 independent experiments). (c,d) Tumor cells were pre-treated with sialidase (closed circles), or P3-FAX (open circles) (together referred to as Sia) (c: 10 donors from 4 independent experiments; d: 8 donors from 3 independent experiments). Neutrophils were stimulated with G-CSF/IFNγ overnight. The bars show mean ± SEM. Statistics: (a,b) paired t-test; (c,d) one-way ANOVA with Sidak correction; ns, not significant; *, p < 0.05; **, p < 0.01. ADCC, antibody-dependent cellular cytotoxicity; Tmab, trastuzumab; Cmab, cetuximab.